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When Alois Alzheimer discovered that the postmortem brains of his 
severely demented patients contained proteinaceous amyloid plaques, 
he wondered whether these deposits caused or resulted from neuro-
degeneration1. A century later, this question has been vigorously investi-
gated and debated, but not definitively answered. Protein aggregation of 
some type is now also known to be a characteristic feature of Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (ALS), Huntington’s disease 
(HD) and many less prevalent neurodegenerative diseases. However, the 
fibrillar deposits that are found in postmortem diseased brains — for 
example, the amyloid plaques noted by Alzheimer, the Lewy bodies 
of PD and related diseases, and the nuclear inclusions of HD — can 
be present in the brains of asymptomatic individuals and do not cor-
relate to the severity of disease at time of death. Spurred on by a greater 
understanding of the in vitro protein fibrillization process, a search for 
a specific neurotoxic prefibrillar aggregate and the pathway by which it 
causes neuronal dysfunction, death and disease is underway. 
The precise relationship between protein aggregates such as the extra-
cellular amyloid plaques and intracellular neurofibrillary tangles that 
characterize the Alzheimer’s disease (AD) brain and the neurodegenera-
tion that produces symptoms has not been determined (Fig. 1). The pos-
sibility that protein aggregation causes neurodegeneration (as opposed 
to resulting from it) returned to centre stage with the discovery that a 
gene linked to autosomal dominant familial AD encodes a precursor 
(amyloid precursor protein, APP) of the amyloid-β protein (Aβ)2. Aβ is 
a 4-kDa peptide that comprises the least soluble, fibrillar component of 
AD amyloid plaques3,4. During the past 15 years, a working hypothesis 
has been developed implicating protein aggregation as the trigger of the 
cascade of events that result in neurodegeneration and disease5. This 
model, which is known as the ‘amyloid hypothesis’, has evolved with our 
understanding of the process of protein aggregation and has withstood 
concerted efforts to disprove it. In recent years, the hypothesis has been 
generalized as it has become apparent that most neurodegenerative dis-
eases are characterized by protein aggregates, albeit of varying composi-
tion. This review briefly summarizes the key experiments that led to the 
working hypothesis, but focuses on recent experimental findings that 
purport to test elements of the working model.
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The amyloid hypothesis has been shaped by evidence drawn primarily 
from three disciplines: neuropathology, genetics and biophysics. Each 
class of evidence is powerful, but each also has limitations. Pathological 
studies have focused on defining and refining the correlation between 
protein deposits, neuronal dysfunction, neuronal loss and severity of 
symptoms at time of death. Because studies of human tissue rely on 
postmortem samples, it is difficult to glimpse the early stages of dis-
ease during which the triggering species is most likely to be observable. 
However, this critical period is theoretically observable in living patients 
by brain imaging. Recent advances towards the in vivo detection of 
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Figure 1 | Fibril formation and disease are linked. Two mutually exclusive 
hypotheses have been proposed to explain the correlation between 
neurodegenerative disease and fibrillar-protein deposits in the postmortem 
diseased brain. a, Hypothesis one: human neurodegenerative disease causes 
fibrillar deposits, but protein aggregation has no causal role. b, Hypothesis 
two: fibrillar protein deposits cause neurodegenerative disease. The tissue 
image is from an AD brain and shows an amyloid plaque surrounded by 
intraneuronal neurofibrillary tangles.
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amyloid plaques in human patients with AD6–8 mean that it may soon be 
possible to follow the natural history of protein aggregation and correlate 
it with disease progression (Box 1) . In the meantime, studies of animal 
models have provided detailed information about certain phenotypes 
of the human disease9,10.
Genetic data are clearly relevant to human AD and have been instru-
mental in the building of a circumstantial case to support existing models 
of pathogenesis. The genes that have been linked to disease are predomi-
nantly of two types: familial and susceptibility factors. Several genes of the 
former type have been identified, and, when mutated, these cause rare, 
early-onset forms of disease. Examples include the genes encoding APP, 
which is involved in familial AD, and α-synuclein, which is involved in 
familial PD. Whether these monogenic subtypes are representative of the 
vast majority of cases, which are believed to originate from a complex 
mixture of genetic and perhaps environmental factors, is debatable (see 
below). The latter type of disease–gene link is based on a susceptibility 
factor, such as apolipoprotein-E genotype in AD11 or UCH-L1 genotype 
in PD12. Although these susceptibility factors are found in many patients, 
it is difficult to translate their subtle effects into a working hypothesis. 
Finally, biophysical studies have been increasingly influential in this 
field owing to their ability to provide a mechanistic rationale to better 
explain the effects of disease-causing mutations — for example, why 
the Aβ42/Aβ40 ratio is more critical than the total amount of Aβ pro-
duced13. The obvious shortcoming of such studies is that the idealized 
experimental systems that they require bear little resemblance to the 
human brain. Moreover, the pathological processes are difficult to study 
in vitro, because, unlike biologically necessary processes (such as the 
complement cascade) or structures (for example, the proteasome), pro-
tein aggregation has not been optimized by evolution and is difficult to 
reconstitute in an artificial environment (in fact, evolution has probably 
done its best to reduce protein aggregation). 
This review discusses and evaluates a series of increasingly detailed 
hypotheses that seek to explain the relationship between protein 
aggregation and neurodegenerative disease. We focus on AD, because it 
set the historical course for the development of the field. AD is also the 
most prevalent human neurodegenerative disease, and, for that reason, 
is the subject of intense drug-development efforts. However, examples 
from other neurodegenerative diseases are discussed where appropriate. 
We also examine the state-of-the-art working hypotheses, asking what 
can be done to refine and clarify the current models, and more impor-
tantly, what needs to be done in order to produce disease-modifying 
treatments for neurodegenerative diseases and to identify presympto-
matic individuals who could benefit from such treatments.
Fibrillar aggregates could be the cause or effect of disease 
The two early hypotheses (Fig. 1) in this field were predicated on the 
fact that fibrillar deposits were the only observable proteinaceous 
abnormalities in postmortem human tissue. The two are mutually 
exclusive, but do not, as explained below, encompass all possibilities: 
both could be wrong. Although they differ in terms of the causal rela-
tionship between protein fibrils and disease, both posit that fibrillar 
aggregates and disease are linked. 
As the list of neurodegenerative diseases characterized by fibrillar 
aggregates grew14, it became apparent that subtypes of several such 
diseases are not characterized by the presence of fibrillar deposits in 
the brain. This finding indicates that fibrillar deposits are not generally 
coupled to disease and, therefore, that hypotheses one and two are both 
incorrect. It is possible that diseases that do not show fibrillar aggrega-
tion, which include Gerstmann–Straussler syndrome (a genetic prion 
disease)15, autosomal recessive juvenile parkinsonism (AJPR, a juvenile-
onset form of PD)16 and sporadic ALS17, are not representative of most 
neurodegenerative diseases. However, the number and size of plaques in 
a postmortem AD brains do not correlate with the severity of symptoms 
at the time of death18,19, which also argues against hypotheses one and 
two. Finally, another fact that conflicts with the second hypothesis is that 
amyloid plaques are found throughout the cortex of many cognitively 
normal 70-year-olds20. 
Fibrillar aggregates are an epiphenomenon of disease
So, a revised hypothesis is necessary to explain the qualitative, but not 
quantitative, correlation between fibrillar deposits and disease. This 
model (hypothesis number three, Fig. 2) allows for the extreme situ-
ations described above — prevalent deposits accompanied by little or 
no disease on the one hand and severe disease with little or no deposits 
on the other. 
It has been estimated that neurodegeneration associated with AD and 
PD starts 5 to 10 years before symptoms warrant a diagnosis. In the case 
of PD, imaging studies have shown that loss of 50% of the substantia 
nigra’s dopaminergic neurons is tolerated; symptoms typically appear 
when 70% have been lost81. The development of methods to diagnose 
these diseases presymptomatically has not been a commercial 
priority, because available therapies target only the symptoms, not the 
underlying disease. However, this situation is about to change, as the 
use of therapies that slow the underlying disease (Box 2) will be greatly 
increased if disease can be diagnosed and treated presymptomatically 
(Fig. 4). As more genetic risk factors emerge, it will be possible to assess 
risk, but in order to justify treatment, it will be necessary to directly 
measure the disease process. 
This is possible for PD, because the affected region of the brain is 
localized and excellent methods for imaging dopaminergic neurons 
are available. However, in the case of AD, direct imaging of protein 
aggregates may provide a more sensitive measure. William Klunk of the 
University of Pittsburgh has developed a positron emission tomography 
imaging reagent that targets fibrillar amyloid plaques and allows 
their detection in vivo6. However, given that fibrillar amyloid occurs 
relatively late in the disease process, it would also be useful to develop 
analogous reagents that target early Aβ-derived aggregates. A recent 
study in transgenic AD mouse models47 used classical biochemical 
separation methods to correlate a non-fibrillar Aβ-containing species 
(Aβ*56) with the appearance of an AD-like phenotype. An analogous 
study, correlating an early Aβ aggregate with the first clinical signs 
of AD, would require the development of new technology and would 
have enormous practical consequences. A time can be imagined when 
individuals with a relative risk of >2.0, on the basis of genetic factors, 
would be routinely imaged at the age of 50 using such a reagent 
(Fig. 4). If abnormal Aβ aggregates were present, treatment with a 
disease-modifying drug could begin immediately. This approach might 
effectively ‘cure’ many cases of AD. 
Box 1 | Imaging aggregates may allow presymptomatic diagnosis
Figure 2 | Fibrillar deposits are not quantitatively correlated with 
disease. There is a qualitative, but not quantitative, correlation between 
fibrillar deposits and disease. One perturbation initiates both fibril 
formation and disease (lightning bolt), although the agent responsible for 
this is unknown.
Disease
Disease
Severe disease with little or no deposits
Prevalent deposits but little or no disease
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According to this hypothesis, many different events (the lighting bolts 
in Fig. 2) could cause both fibril formation and disease. However, given 
that the fibrillar protein aggregates arise from a normally expressed 
protein (such as Aβ or α-synuclein) by a complex pathway, it is logical 
to start by postulating that a precursor to the fibrillar aggregates may 
be the triggering factor21. This hypothesis is supported by studies in 
animal models, which reinforce the conclusion that fibrillar deposits are 
not directly related to disease22–24, and in some cases demonstrate that 
fibrillar deposits and disease-like phenotype are anticorrelated. Thus, 
perturbations that increase deposits decrease the disease-like phenotype 
and vice versa23,25,26. The in vitro discovery and characterization of pre-
fibrillar protein aggregates provided a framework for this hypothesis.
Protofibrils are early intermediates in fibril formation 
Although conventional light microscopic analysis of postmortem AD 
brains revealed only fibrillar protein deposits, immunostaining with 
antibodies to Aβ allowed detection of another type of Aβ deposit, 
known as diffuse amyloid27. This deposit lacks fibrillar substructure 
and was  proposed to be a precursor to fibrillar amyloid. In contrast to 
the fibrillar deposits, which can be extracted from the brain because 
of their unusual stability, diffuse amyloid proved impossible to extract 
and characterize28. Therefore, the first non-fibrillar Aβ aggregates to be 
characterized were produced in vitro, from synthetic Aβ. 
Two groups, using complementary methods, demonstrated that Aβ 
produces non-fibrillar aggregates, which are consumed as fibrils are 
formed29,30. These species were designated protofibrils, because the time 
dependence of their formation and the disappearance of their secondary 
structure (primarily β-sheet) were consistent with their being an inter-
mediate in the fibrillization process (whether or not protofibrils are on 
the direct pathway from monomers to fibrils is still unclear). Notably, 
both groups reported that Aβ42 forms protofibrils more rapidly than 
Aβ40, which is consistent with the fact that Aβ42 is much more strongly 
correlated with the disease process. 
Subsequently, other non-fibrillar Aβ aggregates have been described, 
including Aβ-derived diffusible ligands (ADDLs)31, Aβ amylosphe-
roids32, membrane-associated Aβ oligomers and annular Aβ proto-
fibrils33,34. How these species are related to one another is difficult to 
determine, because the conditions for their formation and characteri-
zation vary widely (Fig. 3). Furthermore, although it is likely that these 
metastable oligomeric species35 assemble in a stepwise process involving 
Figure 3 | Disease and fibril formation may have a common cause. A 
number of factors have been proposed to trigger protein oligomerization 
(protofibril formation) and disease. Whether protofibrillar aggregates are 
the cause of disease is uncertain, but circumstantial evidence supports a 
pathogenic role for these structures.
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Three therapeutic strategies for Alzheimer’s disease, all based on 
reducing the amount of protofibrillar Aβ aggregation ((Aβ)n), have 
reached phase II clinical trials. Each involves a different mechanism (see 
panel).
The first of these is Elan’s Aβ vaccine. Inoculation of mice with an 
Aβ-derived immunogen resulted in the reduction of amyloid plaques82 
and a degree of rescue of some AD-like phenotypes24,83. In subsequent 
animal studies, it was shown that passive immunization, by infusion of 
Aβ-directed antibodies, has a similar effect84, leading to the hypothesis 
that the vaccine causes redistribution of Aβ from the brain into the 
periphery, where it can be degraded85 (1). A reduction in brain Aβ would 
slow or even stop new aggregation, leading to a decrease in the rate of 
neurodegeneration. In addition, such a reduction could lead to complete 
resolution of amyloid plaques, which seem to be in dynamic equilibrium 
with monomeric Aβ and thus may be actively cleared. 
A second strategy (2) involves the inhibition of all Aβ aggregation 
by binding monomeric Aβ with a small molecule (X; Neurochem’s 
‘Alzhmed’ (tramiprosate)) that is thought to be a proteoglycan mimic. 
This reduces amyloid-plaque formation in mouse models (and also 
rescues certain AD-like phenotypes)86. The compound is well-tolerated 
and can cross the blood–brain barrier. Phase II trials suggested that 
a subset of patients with mild AD experienced some improvement 
in cognitive measures after receiving treatment for more than 1 year 
(http://www.neurochem.com/ResearchActivities.htm). Phase III trials, 
the ultimate determinant of efficacy, are underway. 
A third strategy (3) involves the reduction of Aβ42 production from 
APP (and Aβ42 aggregation), by modulating γ-secretase/presenilin 
activity. This strategy originated with the epidemiological finding 
that chronic arthritis patients had a lower incidence of AD87. It was 
determined that the use of some, although not all, non-steroidal anti-
inflammatory drugs (NSAIDs) was responsible for this effect, and that 
the efficacy of NSAIDs did not correlate with their ability to inhibit 
cyclooxygenase 2 (COX2)88. Myriad Genetics (http://www.myriad.
com) is developing a compound, MPC-7869 (R-flurbiprofen, known 
as ‘Flurizan’), that is one component of the racemic drug Flurbiprofen 
(Ansaid) and is itself inactive with respect to COX2 inhibition. MPC-
7869 has been shown to reduce the levels of Aβ42 in cell culture89 and 
in animal models of AD90 by modulating the activity of γ-secretase, and 
is currently being evaluated in phase III clinical trials. It is hoped that this 
compound will not exhibit the side-effect profile associated with COX2 
inhibitors. In a phase II study, patients with mild AD showed a decreased 
rate of decline in several clinical measures of AD severity, although 
moderately affected patients showed no significant improvement. 
Several pharmaceutical companies have reported that γ-secretase 
inhibitors, which lower Aβ42 and Aβ40 by an active-site-directed 
mechanism, are entering phase II trials. 
An alternative strategy to reduce aggregate levels involves the 
stimulation of aggregate degradation (possibly by autophagy). 
Finally, the idea that the promotion of fibril formation (at the expense, 
presumably, of protofibril) would be therapeutic is based on the 
aggresome proposal of Kopito91 and has shown some merit in a 
Drosophila model of PD25 and in cell culture. However, this strategy 
carries considerable risk, because fibrils themselves may be toxic71. 
Box 2 | Clinical trials for strategies to reduce Aβ aggregation in AD
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low-molecular-weight oligomers, the relative importance of these is dif-
ficult to assess because they are too unstable to characterize36–38.
The intermediacy of stable, structured oligomers is a common feature 
of in vitro fibrillization by many disease-associated proteins, including 
α-synuclein39,40, huntingtin41 and islet amyloid polypeptide42,43, as well 
as by fibril-forming proteins that are unrelated to disease44. Non-fibril-
lar aggregates have also been isolated from cell culture45,46, from the 
brains of animal models of AD21,47 and from diseased human brains48–51. 
Annular pore-like aggregates have been observed during the in vitro 
fibrillogenesis of many well-characterized amyloid-forming proteins52. 
Annular α-synuclein-containing structures, similar in morphology to 
the structures formed in vitro, have been isolated from postmortem 
brain tissue of patients with multiple system atrophy (MSA) (ref. 51 and 
H.A.L., unpublished observations). MSA, like Parkinson’s disease and 
diffuse Lewy-body disease, is characterized by α-synuclein deposition 
in the form of cytoplasmic Lewy bodies.
Fibrillar aggregates and disease may have a common cause 
A revised model of pathogenesis, which takes into account the com-
plexity of the fibrillization process, states that one perturbation, or a 
combination of several (Fig. 3, lightning bolt), causes protofibril forma-
tion, fibril formation and disease. Whether fibril formation is caused 
by protofibril formation, as shown in Fig. 3, or merely co-occurs with 
protofibril formation is not as important, from a drug development 
perspective, as defining the relationship between protofibril formation 
and disease (dashed arrows). It is tempting to speculate that protofibril 
formation may cause both fibril formation and disease, but first, the 
possibility that protofibril formation and disease are caused by elevated 
levels of monomer protein must be considered (hypothesis number 
four; Fig. 3). 
Accumulation of protein monomers is not the cause
Neurodegeneration and the expression levels of certain disease-associ-
ated proteins are clearly related. For example, triplication53 or duplica-
tion54 of the α-synuclein gene causes PD, and overexpression to a lesser 
extent due to a promoter polymorphism increases an individual’s risk of 
PD55. This dependence is consistent with aggregation being important 
for disease, but is it possible that the monomeric protein independently 
causes both aggregation and disease (Fig. 3, hypothesis number four)? 
Several facts indicate (but do not prove) that the monomeric proteins 
are non-toxic. First, the disease-linked proteins — such as α-synuclein 
and superoxide dismutase (SOD1, known to be involved in ALS) — are 
highly expressed in the normal brain. Second, the disease-linked pro-
teins are not homologous at the level of primary sequence or native ter-
tiary structure, making it difficult to imagine that this diverse group of 
monomeric proteins activates a common toxic mechanism. However, all 
of the aggregates are characterized by β-sheet secondary structure that 
may be responsible for shared mechanisms of toxicity. Third, many of the 
mutations that cause familial neurodegenerative diseases do not signifi-
cantly alter the encoded protein’s native structure, but reduce its stability 
and hence its steady-state level in vivo while accelerating its aggregation 
in vitro (this is well documented for AD56, PD39,57–59 and ALS60). For 
example, the level of mutant SOD1 in the blood of patients with familial 
ALS is considerably lower than the level of wild-type SOD1, which is 
inconsistent with the monomeric protein’s being toxic (furthermore, the 
amount of mutant protein is inversely correlated with the aggressiveness 
of disease)61. Fourth, cell death in neurodegenerative diseases exhibits 
stochastic behaviour and seems to be highly dependent on the level of 
protein — that is, small changes in expression level have a notable effect 
on disease onset and progression62. This nonlinear dependence is not 
consistent with the protein monomer’s being the pathogenic species, but 
is easily explained by a protein-aggregation mechanism. 
Finally, three features of monogenic neurodegenerative diseases are 
inconsistent with the fourth hypothesis. First, the age of symptom onset 
in Huntington’s disease does not depend on the dosage of the abnormal 
gene (in other words whether it is heterozygous or homozygous)63. This 
finding is inconsistent with hypothesis number four, but can be explained 
by a seeded-polymerization model in which aggregation is nucleated 
by the product of the abnormal gene, and the aggregate can then grow 
equally well with either the mutant or the wild-type protein64. 
Second, although an elevated level of plasma Aβ42 is a risk factor for 
sporadic AD65, several presenilin mutations linked to familial AD do 
not affect Aβ42 levels and decrease Aβ40 production (however, most 
familial-AD-linked presenillin mutations increase Aβ42)66. This effect 
is inconsistent with any hypothesis contending that Aβ42 and/or Aβ40 
elevation alone causes familial AD. 
Third, the fourth hypothesis is difficult to reconcile with a phenom-
enon observed in sporadic prion disease67 and familial ALS68,69, whereby 
mutations or polymorphisms on separate alleles of the gene encod-
ing the aggregating protein (the prion protein and SOD1, respectively) 
modulate the resultant disease. This conflicts with the idea of a protein 
monomer’s being responsible for neurotoxicity, in which case the effects 
of two mutations should be additive. 
Figure 4 | Better diagnosis and presymptomatic treatment would 
drastically reduce the incidence and prevalence of neurodegenerative 
diseases. a, A diagram showing the loss of functional neurons over 
time that is characteristic of AD. Clinical diagnosis occurs when the 
disease is well underway, as symptoms do not become obvious until 
considerable neurodegeneration has occurred. b, A drug that slowed 
disease progression/neuronal loss, if started at clinical diagnosis, would 
have a significant effect on the impact of disease. c, If the same drug could 
be administered presymptomatically to patients diagnosed by, for example, 
imaging methods, the disease might not progress to the point at which 
symptoms become obvious. 
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All of the data discussed above are consistent with the idea that non-
fibrillar protein aggregates cause disease (hypothesis number five; Fig. 
3). This hypothesis explains the lack of a gene-dosage effect in HD. It also 
explains why lowering Aβ40 can cause familial AD — Aβ40 inhibits the 
fibrillization of Aβ42 (by stabilizing protofibrils) — and why raising the 
ratio of Aβ42 to Aβ40, whether by elevating Aβ42 or by lowering Aβ40, 
increases the rate of fibrillization70. Finally, the phenomenon of com-
pound heterozygosity is consistent with the fifth hypothesis, because 
intermolecular interactions are critical for determining aggregation rate 
and disease onset and progression. 
Protofibrillar aggregates may trigger disease 
A demonstration that clinical status and the abundance of certain 
prefibrillar protein aggregates are not quantitatively correlated would 
disprove the fifth hypothesis. However, at present this experiment is 
not possible, because there are no available imaging methods capa-
ble of tracking the early stages of protein aggregation in vivo (Box 1). 
This hypothesis could also be disproved if a drug that could selectively 
inhibit Aβ oligomerization and fibrillogenesis did not slow disease 
progression. In fact, three very different therapeutic strategies for 
AD that each seek to inhibit Aβ aggregation have shown some prom-
ise in reducing AD symptoms in phase II clinical trials (Box 2). It is 
important to note that the fifth hypothesis suggests that if fibrils are 
non-toxic (this is still an open question71), compounds that promote 
the conversion of early aggregates into fibrillar aggregates could slow 
disease progression. 
Several protofibrillar aggregates may be neurotoxic
Because it is not currently possible to directly correlate the amount of 
a discrete protein aggregate to a human disease (Box 1), efforts have 
focused on cellular and mouse models of disease. Discrete protein 
aggregates have been identified both by in vitro aggregation of disease-
associated proteins and in materials extracted from the brains of mouse 
models47 and human patients50,51. It is important to note that, in all of 
these, the extraction procedures and analysis methods (sodium dodecyl 
sulphate polyacrylamide gel electrophoresis, SDS-PAGE) are known to 
influence the dynamic aggregation process72,73. Thus, it is never clear 
whether the species being manipulated in the laboratory ever existed in 
the tissue of interest (in theory, imaging could clarify this; see Box 1). 
However, bearing this caveat in mind, several compelling correlations 
have recently been reported. In each of these, the monomeric protein 
does not affect the phenotype of interest (providing further evidence 
against the second hypothesis) and in many (but not all71) cases, the 
fibrillar aggregate also has no effect.
Non-fibrillar Aβ preparations enriched in SDS-stable oligomers, 
spherical 4–6-nm aggregates and chain-like aggregates have all been 
shown to be toxic to cultured neurons, to inhibit hippocampal long-term 
potentiation (LTP)31,32,36,74,75, to impair synaptic functions and to disrupt 
cognition and learned behaviour in rats47,76. Non-fibrillar α-synuclein 
aggregates inhibit proteasomal activity77 and induce Golgi fragmenta-
tion78. Furthermore, non-fibrillar aggregate preparations produced from 
several amyloid-forming proteins, regardless of differences in their size 
and/or morphological distribution, have been shown to be toxic to cul-
tured cells/neurons, suggesting that a wide range of different aggregate 
species may be neurotoxic.
The problem with all of the correlative studies done so far is that they 
each reduce a complex human disease to a single measurable phenom-
enon — for example, ‘the memory dysfunction in AD results from LTP 
deficit’. This oversimplification is required in order to reach clear conclu-
sions, but AD (and PD, ALS and other similar disorders) probably results 
from a combination of biochemical, cell biological and systemic events 
(such as LTP deficit) each of which may, in turn, be influenced by one or 
more aggregate species. Ultimately, postmortem pathological data from 
human clinical trials of drug candidates that target specific processes 
(Box 2) will clarify the situation. However, in order to obtain this data, 
we must recognize that our current level of understanding, although 
incomplete, is sufficient for the development of such drug candidates. 
We can change the medical landscape
It is critical to recognize that the onset of the neurodegenerative-dis-
ease process — which proceeds from the start of neuronal dysfunction 
— typically predates the first recognition of symptoms by at least 5–10 
years (Box 1). Thus, if the presymptomatic disease could be diagnosed 
and treated, the prevalence of symptomatic disease could be greatly 
reduced (Fig. 4). Because most neurodegenerative diseases are geneti-
cally complex (HD, which is purely familial and monogenic, is the excep-
tion), presymptomatic diagnosis will require either the discovery of a 
peripheral marker for neurodegeneration that reacts earlier and is more 
sensitive than the traditional symptoms (for example, alteration of gene 
expression in the periphery), or that the process of protein aggregation 
be observable in the brain (Box 1). The development of useful imaging 
technology does not require that the relationship between aggregation 
and disease be explained in detail, only that a prefibrillar target be identi-
fied and that a target-specific probe exist. Once early protein aggregation 
has been detected, the patient will be treated with a disease-modifying 
drug designed to reduce the amount of aggregates in the brain. Once 
again, it would not be necessary to identify one specific target provid-
ing that the strategy used reduced all aggregation — for example, by 
reducing production of the aggregating protein (Box 2) or by stimulating 
aggregate clearance38,79,80. Ultimately, Alzheimer’s 100-year-old question, 
“what is the relationship between protein aggregation and neurodegen-
eration?” cannot be answered until the effects of such compounds on 
human disease are evaluated. The clinical trials will be large, time-con-
suming, risky and expensive, but we cannot afford to wait.  ■
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